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Abstract 
The prevention and treatment of infectious diseases is highly dependent on the availability of reliable diagnostic tests 
and protective or therapeutic vaccines. There also exists an urgent need to develop reliable biomarkers to monitor 
treatment success and to predict disease progression from asymptomatic to symptomatic disease in several infectious 
diseases. The elucidation of the disease-relevant antigens that elicit the protective immune responses is critical and 
required for the development of diagnostics and treatments.  Here we present a novel “T cell driven approach” that 
permits the direct identification of pathogen epitopes and protein antigens capable of triggering specific T cell 
responses upon immunization in humans.  
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1. Introduction 
The elucidation of the disease-relevant antigens that elicit protective immune responses is critical and 
required for the development of diagnostics and treatments.  Here we present a novel “T cell driven 
approach” that permits the direct identification of pathogen epitopes and protein antigens that trigger 
specific T cell responses upon immunization in humans. This approach includes a single pathogen in vitro 
stimulation, the generation of pathogen specific T cell clones, the evaluation of their specificity by 
multiple cytokine production, and the screening of the clones with positional scanning peptide libraries. 
PBMC from smallpox vaccinated donors were used to generate vaccinia specific CD4+ T cell clones. The 
peptide specificity of these T cells was elucidated in a completely unbiased fashion by screening each of 
the clones with positional scanning libraries composed in total of trillions of peptides. Ten novel epitopes 
and their corresponding protein antigens from vaccinia virus that trigger CD4+ responses upon smallpox 
vaccination in humans were identified. GM-CSF, while not a standard cytokine used for monitoring T cell 
responses against vaccines or infections, was found to require lower antigen concentration for its 
production than other cytokines, such as IFN-γ, IL-2, and TNF-α. Furthermore, a comprehensive analysis 
of the reported immunogenicity of the vaccinia proteins is presented. 
2. Results 
The overall approach presented in this study is summarized in Figure 1.  The approach is T cell driven 
because it is centered on the expansion and characterization of T cells in response to the vaccine or 
pathogen of interest.  The elucidation of the specificity of the T cells is carried out using positional 
scanning libraries composed of peptides that represent an unbiased source of antigens.  The combination 
of the screening results of the positional scanning and a biometrical analysis leads to the elucidation of the 
peptide and antigen specificity. 
   
 
 
 
 
 
 
 
 
 
 
One of the main obstacles to the study of antigen-specific human T cells is their low frequency in 
PBMC samples. To overcome this, CD4+ T cell lines specific to vaccinia virus were generated to expand, 
at least in part, the vaccinia specific T cells that were generated in vivo upon immunization. In this regard 
we [1] and others [2] have shown that pathogen-specific T cells from infected or immunized subjects are 
successfully expanded with a single in vitro stimulation with the pathogen. Figure 2 shows the comparison 
on the frequency of pathogen-specific cells in ex vivo PBMC and in vaccinia-stimulated lines. The 
percentage of vaccinia specific T cells was determined by intracellular staining of TNF-α and IFN-γ 
production upon vaccinia stimulation. Clearly, in the vaccinia-stimulated line the frequency of cytokine 
producing CD4+ and CD8+ T cells was successfully expanded.   
 
16   Valeria A. Judkowski et al. /  Procedia in Vaccinology  6 ( 2012 )  14 – 20 
 Author name / Procedia in Vaccinology  00 (2011) 000–000 3 
Once T cell lines are generated, the second step is the generation of T cell clones by limiting dilution 
following expansion using phytohemagglutinin (PHA) and allogeneic feeders. Clones that grow to large 
numbers (> 5 million cells) are characterized for clonality by flow cytometry using a panel of anti-Vβ T 
cell receptor antibodies. A fundamental part of the analysis is the choice of the readout that will be used to 
determine if a given T cell line or clone is specific to the pathogen of interest. In this regard, and as part of 
this study, we have shown the importance of evaluating a large number of cytokines, and not only IFN-γ 
as it has been reported in the majority of vaccinia T cell specificity studies. The evaluation of 22 cytokines 
was carried out using the multiplex assay and resulted in the selection of 6 cytokines (GM-CSF, IFN-γ, 
IL-2, IL-4, IL-13 and TNF-α) to characterize the specificity of vaccinia clones [1].  The advantage of 
using TNF-α and GM-CSF instead of IFN-γ for the selection of vaccinia specific clones is clearly shown 
in Figure 3.  Figure 3A and 3B show the number of positive clones, and their corresponding percentage, 
that were identified by ELISA and Multiplex assay, respectively.  Only 10% of the 87 clones tested by 
ELISA and 24% of the 28 clones tested by Multiplex assay produced IFN-γ.  These results clearly 
illustrate the importance of using TNF-α and GM-CSF production as readouts of vaccinia CD4 T cell 
responses since the large majority of the clones would have been missed if only IFN-γ would have been 
monitored. Furthermore, we found that the detection of GM-CSF in response to mixtures of a positional 
scanning library represents a reliable and optimal readout.  In addition, the determination of cytokine 
production at decreasing concentration of the peptides, identified using the positional scanning library, 
showed that the production of GM-CSF requires less peptide than TNF-α as well as other cytokines [1]. 
We are currently characterizing the immune response to other infections evaluating various cytokines by 
multiplex assay and GM-CSF and TNF-α are among the cytokines that appear to be important.    
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Once clones are selected based on their specificity to the pathogen of interest and once they are grown 
to large numbers they are screened with positional scanning libraries in order to determine the epitope and 
protein specificity. In our recently published vaccinia specificity study, 10 novel epitopes and their 
corresponding protein antigens from vaccinia virus that trigger CD4+ responses upon smallpox 
vaccination in humans were identified [1]. We have evaluated and compared the performance efficacy of 
T cell driven approaches (including ours), and MHC approaches that have been reported by others in the 
elucidation of vaccinia epitopes recognized by human CD4+ T cells.  This analysis takes advantage of the 
multiple reports on vaccinia specificity and was carried by compiling the reported vaccinia CD4+ epitopes 
and the recognition of the vaccinia proteins by human CD4+ T cells [3] and antibodies [3-7]. Each of the 
vaccinia proteins was assigned a percentage of recognition that was determined by dividing the number of 
subjects that showed protein recognition by the total number of subjects tested (76 or 126 for antibodies 
and 11 for T cells).   Based on the overall distribution of recognition (shown on the top graphs of Figure 
4) and the number of subjects tested we established a cutoff for a protein to be considered predominantly 
recognized. This cutoff resulted in >40% and >10% for CD4+ T cell or antibody responses, respectively.   
Using these thresholds 31 out of 180 proteins were determined as predominantly recognized by CD4+ T 
cells and 21 by antibodies.   In addition, the compilation of all the reported vaccinia epitopes recognized 
by human CD4+ T cells using T cell and MHC driven approaches revealed that epitopes have been 
identified for 25 and 48 vaccinia proteins, respectively.  The percent of recognition for the proteins for 
which epitopes have been reported using T cell approaches and MHC approaches are shown in the middle 
and bottom bar graphs respectively in Figure 4.  The proteins that we have identified using the approach 
presented in this study are: D13L, F13L, H5R, A10L, L1R, A7L, A6L, E1L, A28L and D1R (denoted 
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with * in the middle bar graphs of Figure 4).  Strikingly, 6 out of the 10 identified proteins (D13L, A7L, 
F13L, A6L, A10L and H5R) are within the 31 predominantly recognized proteins by CD4+ T cells 
(percentage of recognition >40%) and 5 (D13L, F13L, H5R, A10L and L1R) are within the 21 
predominantly recognized proteins by antibodies (percentage of recognition >10%). Furthermore, the pie 
graphs represent the percentages of the predominantly recognized vaccinia proteins for which epitopes 
were identified using the two different approaches. These percentages suggest that in general T cell driven 
approaches are more effective than MHC approaches in identifying predominantly recognized vaccinia 
proteins. Table 1 shows the identity, temporal expression [8] and function of the most prevalently 
recognized proteins determined either by CD4+ T cell or antibody responses. Interestingly, most 
immunoprevalent proteins have late temporal expression which is in agreement to reported findings that 
show that CD8+ responses preferentially recognize antigens that are expressed early during the viral 
lifecycle whereas CD4+ T cell responses revealed a significant preference for late proteins (reviewed in 
[9].  The analysis described above suggests that “T cell driven” approaches, and in particular the strategy 
presented here, identify peptides derived from highly immunoprevalent vaccinia proteins. We then 
performed a statistical analysis comparing the probability of these findings to random sampling. For 
example, if a random sample of 10 proteins were selected from the 180 proteins analyzed by CD4+ T cell 
responses, the probability that 6 or more would be among the 31 predominantly recognized proteins 
would be only 0.21%.  Similarly, if a random sample of 10 proteins were selected from the 181 proteins 
analyzed by antibody responses, the probability that 5 or more would be among the 21 predominantly 
recognized proteins would be 0.23%. The percentage of predominantly recognized proteins that we 
identified is about 60%, which is clearly larger than the random probabilities, and indeed the above 
probabilities indicate that the method used in the present study yields results significantly better than 
random selection.   
3. Conclusions 
A clear limitation in the discovery and evaluation of immunoprevalent antigens is the fact that the 
approaches are based first on the pre-selection of pathogen proteins or peptide antigens, and then on the 
identification of positive responses in bulk T cell populations. In contrast, our approach does not require a 
priori knowledge of pathogen antigens, and is not restricted by HLA haplotype. The approach presented 
here can be used to identify potential immunodominant and subdominant epitopes (and their 
corresponding proteins) to detect and induce parasite specific immune responses in upon infection or 
immunization. Furthermore, the parasite proteins identified are by definition immunogenic in humans, as 
they are recognized by T cells expanded in vivo during infection or vaccination.  
Our results support the notion that the cytokines selected to profile CD4+ T cell specific responses should 
not rely only on IFN-γ secreting cells, but on assessing multi-cytokines at different time-points and by 
using different readout technologies. We believe that further efforts in the development of miniature T 
cell activation assays will be very beneficial to reduce the number of clonal CD4+ T cells required to test 
positional scanning libraries and to define the spectrum of specificities with higher throughput. In 
summary, we show that the single pathogen in vitro stimulation, the evaluation of pathogen specificity by 
detecting multiple cytokines, and the screening of T cell clones with positional scanning libraries using 
GM-CSF as readout of activation constitutes a novel approach for the elucidation of prevalently 
recognized proteins in response to large pathogens in human samples.  
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